# Pharmacokinetics Shared Resources Core

> **NIH NIH P30** · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · 2020 · $289,295

## Abstract

PROJECT SUMMARY/ABSTRACT— Pharmacokinetics Shared Resource
The Pharmacokinetic Shared Resource (PKSR) is an SJCCC-managed shared resource with the overarching
goal of enabling more effective and safer anticancer drug use in children. We accomplish this goal by facilitating
high-quality, competitively-funded, peer-reviewed pharmacokinetic (PK) and pharmacodynamic (PD) research
by SJCCC investigators working in clinical trials and preclinical cancer models. PKSR collaborates with SJCCC
investigators to integrate the highest-quality PK/PD studies into SJCCC preclinical research and Phase I, Phase
II, and Phase III clinical trials via the centralized research infrastructure provided by the core. The PKSR also
supports education and improvement of research efforts at other institutions by offering PK/PD modeling
workshops and a publicly-available, highly-accessed online resource to simulate plasma concentrations of
methotrexate in children. The impact of the PKSR on the cancer research in all 5 Programs is evidenced by the
high level of collaborative publications and key scientific contributions in high-impact journals such as Journal of
Clinical Oncology (n=12), Blood (n=11), Nature Genetics (n=4), and Cancer Cell (n=3). During the last funding
period, 139 SJCCC publications from January 2013–December 2017 used the PKSR, representing 38 (27%)
interprogrammatic and 96 (69%) intraprogrammatic collaborations. These included publications from all 5
Programs: CCSP (n=6), DBSTP (n=35), HMP (n=86), CBP (n=13), and NBTP (n=51). During the index year
(FY2017), 67% of all investigators using the PKSR were SJCCC members (56/83). The PKSR is directed by Dr.
Mary Relling (HMP), who is Chair of the Pharmaceutical Sciences Department and has more than 32 years of
experience in pediatric cancer PK, PD, and pharmacogenomic research. Dr. Kristine Crews is the co-director of
the PKSR, serving in this role since 2005. She has more than 20 years of experience in the areas of clinical
pharmacology, PK, and pharmacogenetics. Together, they supervise a staff of technologists, biomedical
modelers, coordinators, and research nurses who are fully integrated into the clinical research and
pharmaceutical sciences enterprise to ensure that all SJCCC clinical PK/PD research is consistently supported.
Goals for the next period include continuing to support SJCCC PK/PD research to advance the translational
development of anticancer agents for children. Services will be modified, as needed, to accommodate new assay
technologies and modeling approaches and to align with the evolving needs of the SJCCC Programs. The PKSR
will also continue to collaborate with SJCCC investigators on the implementation and support of clinical protocols
involving PK/PD studies. The PKSR anticipates implementing 12 new protocols and supporting 90 individual
projects or protocols each year in the next project period. Lastly, the PKSR will maintain state-of-the art analytical
facilities and bring online new ...

## Key facts

- **NIH application ID:** 9883743
- **Project number:** 5P30CA021765-41
- **Recipient organization:** ST. JUDE CHILDREN'S RESEARCH HOSPITAL
- **Principal Investigator:** MARY V RELLING
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $289,295
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9883743

## Citation

> US National Institutes of Health, RePORTER application 9883743, Pharmacokinetics Shared Resources Core (5P30CA021765-41). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9883743. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*